São Paulo - Delayed Quote BRL

Raia Drogasil S.A. (RADL3.SA)

15.22
-0.08
(-0.52%)
At close: May 16 at 5:07:44 PM GMT-3
Loading Chart for RADL3.SA
  • Previous Close 15.30
  • Open 0.00
  • Bid 15.02 x --
  • Ask 15.28 x --
  • Day's Range 0.00 - 0.00
  • 52 Week Range 0.00 - 30.40
  • Volume 0
  • Avg. Volume 13,063,615
  • Market Cap (intraday) 26.072B
  • Beta (5Y Monthly) 0.24
  • PE Ratio (TTM) 21.44
  • EPS (TTM) 0.71
  • Earnings Date Aug 5, 2025
  • Forward Dividend & Yield 0.31 (2.07%)
  • Ex-Dividend Date Apr 30, 2025
  • 1y Target Est 22.51

Raia Drogasil S.A. engages in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics, dermocosmetics, and specialty medicines in Brazil. It sells its products through stores, telesales, and call centers in the states of São Paulo, Tocantins, and Pernambuco. The company was founded in 1905 and is headquartered in São Paulo, Brazil.

rdsaude.com.br

66,275

Full Time Employees

December 31

Fiscal Year Ends

Recent News: RADL3.SA

View More

Performance Overview: RADL3.SA

Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is IBOVESPA (^BVSP) .

YTD Return

RADL3.SA
30.37%
IBOVESPA (^BVSP)
15.72%

1-Year Return

RADL3.SA
44.33%
IBOVESPA (^BVSP)
8.50%

3-Year Return

RADL3.SA
9.83%
IBOVESPA (^BVSP)
28.60%

5-Year Return

RADL3.SA
19.05%
IBOVESPA (^BVSP)
79.46%

Compare To: RADL3.SA

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: RADL3.SA

View More

Valuation Measures

Annual
As of 5/16/2025
  • Market Cap

    26.07B

  • Enterprise Value

    33.32B

  • Trailing P/E

    21.43

  • Forward P/E

    25.06

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.63

  • Price/Book (mrq)

    4.02

  • Enterprise Value/Revenue

    0.84

  • Enterprise Value/EBITDA

    10.71

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    2.95%

  • Return on Assets (ttm)

    6.76%

  • Return on Equity (ttm)

    18.68%

  • Revenue (ttm)

    39.81B

  • Net Income Avi to Common (ttm)

    1.17B

  • Diluted EPS (ttm)

    0.71

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    470.18M

  • Total Debt/Equity (mrq)

    118.73%

  • Levered Free Cash Flow (ttm)

    1.36B

Research Analysis: RADL3.SA

View More

Company Insights: RADL3.SA

Research Reports: RADL3.SA

View More

People Also Watch